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Nanotechnology has been projected to have a significant 
impact on the future treatment of brain tumors. Specifically, 
nanoparticles have the potential to revolutionize brain 
tumor imaging as well as surgical and adjuvant treatments. 
The translation of current research in nanotechnology into 
clinical practice will rely on solving challenges relating to the 
pharmacology of nanoparticles.
Why NaNoparticles?
One of the key reasons that nanoparticles have promise in 
the treatment of cancer is that they can be targeted to tumors 
through antigen-dependent (specific) or antigen-independent 
(nonspecific) mechanisms. Specific targeting relies on the inter-
action of antigens on the surface of nanoparticles with tumor cell 
receptors. A variety of molecules including peptides (arginine–
glycine–aspartic acid,1 F3,2 and chlorotoxin3), cytokines (inter-
leukin-134), drugs (methotrexate5), antibodies (anti-epithelial 
growth factor antibodies6), and ferromagnetic agents7 have been 
proposed as targeting modalities. Multiple targeting molecules 
can be added to the surface of nanoparticles to tailor targeting of 
brain tumors through a concept referred to as “surface-mediated 
multivalent affinity effects.”1
Nonspecific targeting relies on the preferential extravasation of 
nanoparticles into the brain through vascular access provided by 
blood–brain barrier (BBB) breakdown, which occurs in many 
brain tumors. Other small molecules can also cross BBB defects. 
However, unlike small molecules that diffuse freely into and out 
of a tumor, nanoparticles accumulate within a tumor because 
of the enhanced permeability and retention effect. The effect 
accounts for the observation that nanoparticles are retained 
within tumor tissue after serum levels decline. The enhanced 
permeability and retention effect results from active angiogen-
esis, the expression of vascular mediators of extravasation, and 
altered vascular architecture.8
In addition to their potential for targeting, the physicochemi-
cal properties of nanoparticles make them ideal devices for the 
delivery of compounds to brain tumors. Molecules such as con-
trast agents or drugs can be loaded into the core of a nanoparti-
cle or applied as a coating to its surface. The process of a single 
nanoparticle carrying a large number of drug molecules or ions 
is referred to as “nanoparticle amplification”1 and explains the 
concept of nanoparticles as delivery devices. In addition, mol-
ecules with different functions can be incorporated into a nano-
particle to create multifunctional nanoparticles (Figure 1). The 
size and chemical composition of a nanoparticle can be altered 
to control the efficiency of small-molecule loading.
The performance of nanoparticles in biological systems sug-
gests that by isolating their payload from the surrounding envi-
ronment, they may reduce the systemic toxicity associated with 
conventional chemotherapeutic agents. Moreover, nanoparticles 
create a barrier to degradation of their payload by preventing 
contact with plasma enzymes.
DiagNostic applicatioNs
io Mri contrast agents
One of the most mature applications of nanotechnology to 
the diagnosis of brain tumors is in magnetic resonance imag-
ing (MRI). Various nanoparticles have been developed as MRI 
contrast agents. To date, nanoparticle-based contrast agents 
have been designed with a core of iron oxide (IO) crystals with 
or without a shell of organic material, such as polyethylene 
 glycol (PEG).9–11
The key benefit of nanoparticle-based materials is that they 
may provide better information about the extent of tumor. Both 
gadolinium-based contrast agents and nanoparticle-based con-
trast agents cause enhancement of tumors by passing through 
areas of disrupted BBB where they alter MR signal intensity. 
However, unlike gadolinium, nanoparticle-based contrast agents, 
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such as ultrasmall superparamagnetic IO (SPIO) nanoparti-
cles, are taken up by the phagocytes found at tumor margins.12 
Therefore, areas of tumor not seen with gadolinium-enhanced 
MRI can be detected using IO-based nanoparticles.11 Moreover, 
unlike freely diffusing gadolinium chelates, IO-based nanoparti-
cles tend to persist longer within the tumor and more accurately 
delineate tumor margins.12 Another advantage of nanoparticles 
is their capacity for highly selective molecular tumor targeting. 
It is possible that nanoparticles could be engineered to image 
certain subpopulations of cells, such as stem cells or endothelial 
cells. Various IO nanoparticles under development show prom-
ise as tumor-specific contrast agents.2,13,14
intraoperative brain tumor delineation
The central challenge of brain tumor surgery is achieving a 
complete resection without damaging normal structures near 
the tumor. Achieving maximal resection currently relies on the 
neurosurgeon’s ability to judge the presence of residual tumor 
during surgery. The use of fluorescent and visible dyes has been 
proposed as a means of visualizing tumor margins intraop-
eratively. However, investigators have been hampered by three 
main difficulties: (i) achieving tumor specificity, (ii) achieving 
adequate visual contrast, and (iii) identifying a dye useful for 
a wide range of tumors. Dye-loaded nanoparticles have been 
reported to meet each of these challenges.
IO-based nanoparticles loaded with the near-infrared fluo-
rescing molecule Cy5.5 for intraoperative tumor delineation 
have been created and characterized.13,14 These nanoparticles 
can be visualized in experimental models with fluorescence 
imaging and MRI. Under the appropriate lighting conditions, 
Cy5.5-loaded nanoparticles delineate margins of implanted 
tumors (Figure 2).15
Optical semiconductor nanocrystals, called quantum dots, 
have also been evaluated as a method to visualize brain tumors 
and have been shown to induce fluorescent staining of implanted 
C6 brain tumors.16 However, because of their heavy metal con-
tent, quantum dots are potentially toxic toward normal tissues. 
Moreover, like Cy5.5-loaded nanoparticles, the quantum dots 
characterized to date require a darkened operative field for visu-
alization. Still, it is possible that the composition of the quantum 
dots could be modified to emit light in the visible spectrum.16
We have developed and characterized a nontoxic dye–loaded 
polyacrylamide nanoparticle that shows promise for delin-
eating neoplastic tissue under normal lighting conditions. 
Coomassie-blue loaded nanoparticles have been shown to vis-
ibly stain 9L gliosarcoma cells, and in vivo data are currently 
being collected.
therapeutic applicatioNs
chemotherapeutics
Nanoparticles are in a unique position to enable the develop-
ment of novel chemotherapeutics by facilitating passage of these 
compounds across the BBB or across the blood–tumor barrier 
and delivering drugs to brain tumors at levels that would not 
otherwise be possible. Nanoparticles may also meet the chal-
lenge of efficiently delivering hydrophobic drugs to tumor cells 
and overcoming drug resistance.
Solid lipid nanoparticles (SLNs) are among the best character-
ized, nontoxic, nanoscale devices for brain tumor drug delivery. 
Although the exact mechanism by which SLNs cross the BBB 
and blood–tumor barrier is unknown, binding, endocytosis, and 
phagocytosis by endothelial cells are central components.17 The 
lipid matrix of SLN provides a means of loading drugs such as 
doxorubicin and paclitaxel in a microenvironment that protects 
them from degradation and improves their therapeutic window 
by maximizing release within tumor tissue. Drug-loaded SLNs 
have been shown to enhance tumor concentrations and decrease 
plasma concentrations of doxorubicin and paclitaxel as com-
pared to equivalent drug doses, even without the need for toxic 
surfactants.17 The unloading of drugs within target tumor tissues 
can also be controlled through modification of the SLN surface 
and constituent lipids.18
Similar in composition to SLNs, nanoparticle formulations of 
low-density lipoproteins have also been proposed as novel drug 
delivery devices. Tumor cells preferentially take up low-density 
lipoprotein nanoparticles via corresponding receptors, which are 
a cb
Figure 2 Fluorescent staining of implanted green fluorescent protein (GFP)-
expressing 9L gliosarcoma by nanoparticles containing Cy5.5 (near-infrared dye). 
The tumor is visualized under (a) normal lighting conditions, (b) GFP channel, 
and (c) Cy5.5 channel. The tumor is above the black or white triangle. Adapted with 
permission from Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. 
A multimodal nanoparticle for preoperative magnetic resonance imaging and 
intraoperative optical brain tumor delineation. Cancer Res 63: 8122–8125.
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Figure 1 Schematic diagram of multifunctional polyacrylamide nanoparticle. 
While this nanoparticle contains contrast agents, photosensitizers, and 
F3-targeting peptides, all of these components can be interchanged for other 
small molecules with various functions. The size of the nanoparticle shown is 
~20 nm. Generally larger than circulating proteins (hemoglobin tetramer (6 nm) 
and albumin (8 nm)), nanoparticles range in size from 1 to 100 nm. Adapted 
with permission from Reddy et al. Vascular targeted nanoparticles for imaging 
and treatment of brain tumors. Clin Cancer Res 12: 6677–6686 (2006). Figure 1.
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upregulated in these tissues. The utility of low-density lipopro-
tein nanoparticles as drug delivery devices has been suggested 
by in vitro studies that demonstrate their rapid internalization 
by glioma cell lines.19
Like lipid-based nanoparticles, non-lipid-based nanoparti-
cles consisting of matrices of synthetic biocompatible polymers 
also isolate their payload from the environment. The clinical 
use of doxorubicin20 and paclitaxel21 in gliomas has been lim-
ited by the inability of these drugs to cross the BBB because 
of the p-glycoprotein drug efflux system in endothelial cells. 
The feasibility of employing polymeric doxorubicin-loaded 
nanoparticles for the treatment of brain tumors has been dem-
onstrated in a rat glioma model.20 Similarly, paclitaxel-loaded 
poly(d,l-lactide-co-glycolide) nanoparticles were more cyto-
toxic to C6 glioma cells than was free paclitaxel in vitro, prob-
ably due to internalization and intracellular unloading of the 
drug from the nanoparticles.22 Moreover, when paclitaxel is 
used, poly(d,l-lactide-co-glycolide) nanoparticles eliminate 
the need for coadministration of surfactant. Data from clinical 
trials of Abraxane, a nanoparticle formulation of paclitaxel, in 
cancer patients will help to determine how nanoparticle-based 
drugs may be applied in treating glioma patients.
In addition to enabling the entry of chemotherapeutics into 
tumor cells, nanoparticles can be engineered to potentiate the 
activity of chemotherapeutics by inhibiting the p-glycoprotein 
drug efflux system, which confers resistance to therapy to some 
tumor cells. Specifically, polycyanoacrylate, cetyl alcohol/ 
polysorbate, lipid polymer–based, and surfactant polymer–
based nanoparticles have been shown to potentiate the effects 
of chemotherapeutic agents by inhibiting p-glycoprotein activity 
in glioma cell lines.23 The activity of chemotherapeutic com-
pounds in glioma cells has also been potentiated when they are 
co-incorporated with nanoparticles containing p-glycoprotein 
inhibitors.24
Nonconventional therapeutics
In addition to the delivery of conventional anticancer agents, 
nanoparticles may be capable of delivering gene therapy plas-
mids. Nanoparticles are gaining favor as vectors for gene therapy 
because they cross the BBB more efficiently, can be dosed more 
precisely, and are less immunogenic than traditional vectors. 
Recently, a plasmid encoding proapoptotic Apo2 ligand/tumor 
necrosis factor–related apoptosis–inducing ligand was incorpo-
rated into a cationic albumin-conjugated PEGylated nanopar-
ticle and found to have potent antitumor activity against the C6 
glioma model in vitro and in vivo.25
Attempts at thermotherapy for the treatment of brain tumors 
using focused ultrasound have been hampered by the challenges 
of the electromagnetic properties of the skull and of achieving 
even temperature distribution throughout a lesion.26 An alterna-
tive strategy was developed in which SPIO nanoparticles were 
injected intratumorally and heated via a magnetic field. SPIO 
nanoparticles are well suited for this application since they are 
retained within tumor tissue for the duration of therapy. Injected 
SPIO nanoparticles were first tested in a rat model of glioma and 
shown to be effective in improving survival.27 A recent phase I 
clinical trial suggests that SPIO can be safely administered to 
patients with glioblastoma.26
Photodynamic therapy (PDT) is an experimental adjuvant 
therapy for brain tumors that carries little local or systemic 
treatment associated morbidity. PDT was initially applied clini-
cally to cutaneous and bladder malignancies, which can easily 
be exposed to light. While brain tumors cannot be exposed to 
light as easily, even the deepest brain tumors become exposed 
during surgery. Thus far, the efficacy of PDT for treating brain 
tumors has been limited in clinical trials, probably because of 
the difficulty of creating tumor-specific, sufficient accumulation 
of photosensitizer within neoplastic cells.28 Polymeric nanopar-
ticles offer a solution to this problem by allowing the delivery 
of a large quantity of photosensitizers to tumor cells via tumor-
specific ligands. Reddy et al. have induced long-term remission 
of implanted 9L gliomas through PDT mediated by F3-targeted, 
Photofrin-loaded magnetic nanoparticles.2 The ability of nano-
particles to mediate PDT is an exciting possibility that merits 
further investigation.
Future challeNges
Challenges related to nanoparticle clearance and toxicity must 
be overcome before nanoparticles can be used clinically. While 
the addition of PEG to the nanoparticle surface can prevent 
opsonization and delay clearance,29 the clearance of PEGylated 
nanoparticles through the liver is relatively slow, thereby increas-
ing the risk of toxicity. Because of conflicting evidence in various 
animal models, lack of details about the mechanism by which 
PEG prevents opsonization, and a limited understanding of the 
biochemical properties of PEG polymers for coating nanopar-
ticles, significant experimental work remains to be done before 
PEGylated nanoparticles can be used clinically.30
Beyond preliminary evidence that suggests that nanoparticles 
may have toxicity toward astrocytes and neurons in  culture, 
there are few in vitro data on the toxicity of nanoparticles 
toward the central nervous system. Nonetheless, nanoparticles 
have been used in experimental studies in humans as imaging 
and drug delivery agents without significant adverse conse-
quences. An understanding of the relationship between toxic-
ity and particle size, geometry, pharmacokinetics, and surface 
coating is required before nanoparticles can be used in clinical 
practice.
suMMary
Nanoparticles have the potential to advance the diagnosis, 
operative management, and adjuvant therapy of brain tumors. 
Nanoparticle-based MR contrast agents have the potential to 
visualize portions of tumor, especially along the tumor–brain 
interface, that would have been unclear with conventional MRI. 
In addition, nanoparticles may ultimately improve the complete-
ness of brain tumor resection. Finally, delivery of chemother-
apy and nontraditional therapies to brain tumors will likely be 
improved by nanoparticle-based drug delivery devices. As our 
knowledge of their pharmacology expands, nanoparticles are 
likely to play a central role in the future management of brain 
tumor patients.
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